Sign in
Taking people in United StatesPhase 2

Tests ARCT-032 in adults with cystic fibrosis who cannot take CFTR modulators

Tests ARCT-032 in adults with cystic fibrosis who cannot use modulator drugs.

Key facts

Who runs it
Arcturus Therapeutics, Inc.
Where
Boston, Charleston, Cleveland, Hollywood, Little Rock, Los Angeles, Nashville, Northfield, San Antonio, Seattle, St Louis, Tucson, and Washington D.C., United StatesSee the 13 sitesAlso in 2 other countries, 4 sites
Registry title
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
Status
Recruiting
Phase
Phase 2
People taking part
33 people, planned
Started
12 Dec 2024
Expected to end
Jun 2027
Type of study
Interventional, 4 groups
Treatments tested
  • ARCT-032
Record updated
8 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cystic fibrosis who cannot use or are not taking CFTR modulator medicines. They would inhale the study drug ARCT-032.

Age
18 years or older
Sex
All sexes can join
Disease stage
Confirmed cystic fibrosis. FEV1 (a lung function test) of 40% to 100% of predicted value in cohorts 1-3, and 45% to 90% in cohort 4.
Earlier treatment
Not able to have CFTR modulator therapy, or not taking CFTR modulators for at least 60 days before the first dose (for example because of intolerance, poor response, or no access).

Main reasons for not taking part

  • Illness or medical condition that could add risk or confuse the study results
  • Recent moderate or severe coughing up of blood (hemoptysis)
  • Recent major surgery
  • Solid organ or blood-related transplant
  • Need for extra oxygen while awake, or more than 2L per minute while sleeping

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Confirmed diagnosis of Cystic Fibrosis
  • Not eligible for CFTR modulator therapy or not taking CFTR modulators for at least 60 days prior to dosing (e.g. due to intolerance, poor response, or lack of access to modulators)
  • FEV1 between 40% to 100% (cohorts 1-3) and 45% to 90% (cohort 4, inclusive) of predicted value for age, sex and height

Who cannot take part

  • Recent major surgery
  • Solid organ or hematologic transplant
  • Chronic maintenance systemic corticosteroids exceeding equivalent of daily 15 mg oral prednisone or 30 mg every other day
  • History of illness or medical condition that might pose an additional risk or may confound study results
  • Recent moderate or severe hemoptysis
  • Requirement of supplemental oxygen while awake or > 2L per minute while sleeping
  • Adequate liver and kidney function as determined by lab tests

Where in United States

Also in 2 other countries, 4 sites

  • Boston Children's HospitalBoston, United StatesTaking people
  • Medical University of South CarolinaCharleston, United StatesTaking people
  • Cleveland Clinic FoundationCleveland, United StatesTaking people
  • Joe DiMaggio Children's HospitalHollywood, United StatesTaking people
  • University of Arkansas for Medical SciencesLittle Rock, United StatesTaking people
  • Children's Hospital of Los AngelesLos Angeles, United StatesTaking people
  • Vanderbilt University Medical CenterNashville, United StatesTaking people
  • The Cystic Fibrosis InstituteNorthfield, United StatesNo longer taking part
  • UT Health San AntonioSan Antonio, United StatesTaking people
  • Seattle Children's HospitalSeattle, United StatesTaking people
  • Washington University School of MedicineSt Louis, United StatesTaking people
  • University of ArizonaTucson, United StatesTaking people
  • Children's National HospitalWashington D.C., United StatesNot yet recruiting

About the trial

What the trial wants to find out

ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.

The 4 groups in the trial

  • Cohort 1Treatment being tested

    Dose Level A of ARCT-032, inhaled daily for 28 days

    Treatment: ARCT-032

  • Cohort 2Treatment being tested

    Dose Level B of ARCT-032, inhaled daily for 28 days

    Treatment: ARCT-032

  • Cohort 3Treatment being tested

    Dose Level C of ARCT-032, inhaled daily for 28 days

    Treatment: ARCT-032

  • Cohort 4Treatment being tested

    Dose level B or C of ARCT-032, inhaled once daily for 12 weeks

    Treatment: ARCT-032

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People With Cystic Fibrosis
Plain-language title
Tests ARCT-032 in adults with cystic fibrosis who cannot take CFTR modulatorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
8 May 2026